Published by Alexander Bueso on 1st September 2021
(Sharecast News) - Merck and its Miami-based partner Ridgeback Biotherapeutics have started the third phase of its MOVEe-AHEAD clinical trial for molnupiravir, an investigational oral antiviral therapeutic against infection from Covid-19.
URL: http://www.digitallook.com/dl/news/story/32093783/...